The revolution is underway, and with careful stewardship and continued research, GLP-1based strategies are poised to become an integral part of comprehensive, modern obesity care.
Out of pocket costs for the drugs can run as high as over $1,000 per month
Following extensive clinical testing, including against comparable treatments, tirzepatide was approved in May 2022 by the United State Food and Drug Administration (USFDA) as a type 2 diabetes (T2D) treatment
That approach produces the most predictable results
However, their reliance on non-renewable carbon sources, energy-intensive thermal activation of charcoal, and high costs have prompted the scientific community to seek cost-effective and sustainable alternatives
For a 220-pound starting weight, that puts you somewhere around 187 to 202 pounds